MDM2 (E3 ubiquitin protein ligase)

Extensive sampling, careful morphological observation, immunohistochemical staining and molecular detection of NAB2::STAT6 fusion are helpful for the diagnosis. It appears to have aggressive biological behaviors.

The algorithm also performed robustly in the TCGA-SARC data, although with a slightly different optimal cutoff, likely due to differences in gene panels, depth of sequencing, gene coverage, and bioinformatics pipelines. This study presents an effective strategy for screening DDLPS and potentially other MDM2-amplified sarcomas.

RBM10 mutation is frequent in Japanese patients with NSCLC with EGFR mutation, especially those with L858R or uncommon mutations, and was associated with late-onset and features of indolent tumor growth.

Furthermore, cancer biochemistry has been studied in isolation, one pathway at a time, without considering the complex interactions between proteins and regulatory RNAs, which are characteristic of a living human organism. This work develops a new unified therapeutic theory that identifies novel master regulators of apoptosis as targets for treating cancer regardless of which organ the cancer lies in, through a novel biochemical flowsheet of a universal apoptosis network comprising approximately 100 pathways (80% activation and 20% inhibition), based on a critical analysis of 172 scientific publications that considered all the complex interactions between proteins and regulatory RNAs.

The spirooxindoles 6b, 6k, and 6n attained the most pronounced activity in the MULTI-ARRAY MDM2-p53 complex assay with IC50 values of 1.26, 1.30, and 1.25 µM, respectively, in comparison with nutlin-3 (IC50 = 2.03 µM)...Molecular docking and molecular dynamics simulations justified the observed efficacy. Collectively, this study showcased a new class of potent p53-MDM2/MDMX dual inhibitors possessing a spirooxindole scaffold which can be subjected to future development.

Early-generation MDM2 inhibitors (e.g., RG7112, Idasanutlin) showed limited monotherapy efficacy and dose-limiting toxicities like thrombocytopenia, halting their development at early-phase clinical trials. In contrast, novel MDM2 inhibitors like APG-115 have advanced to Phase II trials, marking a significant breakthrough. Although not yet tested in dedicated osteosarcoma cohorts, their safety and efficacy in MDM2-amplified solid tumors provide a critical foundation for the development of precision medicine and combination regimens for osteosarcoma. Future efforts to accelerate drug development may leverage single-cell sequencing and AI-aided drug design to decipher osteosarcoma heterogeneity and optimize drug profiles for reduced toxicity.

This case highlights the diagnostic challenge posed by cardiac UPS mimicking benign tumors such as myxoma on imaging and the importance of longitudinal imaging review and a high index of suspicion in cases with atypical radiological features of myxoma. It also raises awareness of an unusually indolent behavior of an UPS that otherwise pursues an aggressive course.

ER+ and ER+/PR+ tumors maintain DNA repair and apoptotic competence despite high proliferative signaling, HER2+ and TNBC subtypes display genomic instability and apoptotic evasion. Critically, the study identifies an evolving biological "engine, " transitioning from AKT/hTERT-driven growth in young patients to a MAPK/NF-κB-dominant inflammatory profile and genomic collapse in older cohorts, necessitating age-tailored precision oncology and targeted inhibitors.

Our analysis and a synthesis of the literature confirm that CDKN2A/CDKN2B deletion and PIK3CA mutation are common in both BrBT and MBT, while MDM2 amplification and KRAS/FGFR3 alterations are enriched in MBT. These findings delineate key molecular drivers, reveal therapeutic vulnerabilities, and underscore the need for molecular-guided strategies in these rare tumors.

To our knowledge, this represents only the third reported malignant hepatic glomus tumor with molecular confirmation of CARMN::NOTCH2 fusion. This tumor highlights the diagnostic challenges posed by hepatic glomus tumors, underscores the importance of integrating molecular studies into unusual hepatic neoplasms, and expands the clinicopathologic and molecular spectrum of this exceedingly rare entity.

The patient remained recurrence-free at 12-month follow-up. This case emphasizes the critical role of multimodal medical imaging, rigorous histopathological evaluation, and molecular testing in establishing an accurate diagnosis and guiding appropriate management, while highlighting that Madelung's disease may occasionally present with atypical imaging features, such as nodules and septa which closely mimic a malignant lesion.

At 33 months following completion of RT and 41 months from diagnosis, the patient remains alive and disease-free without evidence of recurrence or significant late toxicity. This case supports the feasibility of incorporating adjuvant RT into a multimodal treatment approach for CIS and suggests that advanced radiation planning techniques may allow safe delivery of curative-intent doses to the heart, although further studies are needed to define its role in this rare malignancy.